Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
0
institutions
Market cap
$64.7M
34M shares
52-week range
$1.28 β $9.50
11% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
www.virios.comNo one on the platform currently holds DWTX.
No tracked institution reports a position in DWTX as of their last filing.
No one on the platform has traded DWTX yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$DWTX Will my CVR shares ever be worth anything?
View on StockTwits β$DGNX $MSS $DWTX β‘οΈβ‘οΈβ‘οΈ WKSP Going parabolic!! πππ SUPER CHEAP!! ππππ ----WKSP----
View on StockTwits β$DGNX $MSS $DWTX THESE TICKERS DON'T JUST COME AROUN FOR NO REASON! well, sometimes they do π BUT STILL! ON WATCH
View on StockTwits β$DWTX dogwood therapeutics to the mooooonnnn π
View on StockTwits β$DWTX Phase 2 trial w/est Jul completion date NCT06848348: https://www.clinicaltrials.gov/study/NCT06848348 Trial Tracker: https://www.fdatracker.com/trial-tracker/
View on StockTwits βRecent $TICKER stream from stocktwits.com β refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $129M | β | $-0.58 | $-0.60β$-0.56 | β | 2 |
| 2027 | $19M | -85.5% | $-0.74 | $-0.83β$-0.65 | β | 2 |
| 2028 | $9M | -49.7% | $-0.74 | $-1.11β$-0.47 | β | 3 |
| 2029 | $57M | +509.1% | $-0.21 | $-0.21β$-0.21 | β | 1 |
Forward consensus Β· growth is YoY vs the prior fiscal-year estimate Β· Fwd P/E at the current price Β· source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.14 | $-0.34 | -142.9% |
| 2026-05-14 | $-0.22 | $-0.15 | +31.8% |
| 2026-03-18 | $-0.86 | $-0.26 | +69.8% |
| 2025-11-06 | $-1.23 | $-8.20 | -566.7% |
| 2025-08-13 | $-1.26 | $-1.99 | -57.9% |
| 2025-05-08 | $-0.77 | $-4.21 | -446.8% |
| 2025-02-26 | $-1.36 | $-5.90 | -333.6% |
| 2024-11-07 | $-1.18 |
| $-2.05 |
| -73.7% |
| $15M |
| β |
| EDSAEdesa Biotech, Inc. | $5.43 | +2.45% | $52M | β |
| ERNAErnexa Therapeutics Inc. | $4.30 | -2.71% | $1M | β |
Source: Financial Modeling Prep Β· peers by sector/industry